| Literature DB >> 34983475 |
Shouyi Yan1,2,3,4, Jiafan Yu1,2,3,4, Wenxin Zhao5,6,7,8, Bo Wang1,2,3,4, Liyong Zhang1,2,3,4.
Abstract
BACKGROUND: Prophylactic central lymph node dissection (PCND) was a basic consensus for patients with papillary thyroid carcinoma (PTC) in China. However, unilateral or bilateral central lymph node dissection (CND) was still controversial. This study aimed at investigating the safety and long-term benefit for the patients undergone with bilateral central lymph node dissection (BCCD).Entities:
Keywords: Central lymph node dissection; Papillary thyroid cancer; Parathyroid protection; Thyroidectomy; Tumor recurrence
Mesh:
Year: 2022 PMID: 34983475 PMCID: PMC8725302 DOI: 10.1186/s12902-021-00909-0
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Characteristics of all included patients are reported
| Characteristics | ICND | BCND | |
|---|---|---|---|
| No. of patients | 296 | 285 | / |
| Age [years; ±SD (range)] | 43.2 ± 11.7 | 43.8 ± 11.5 | 0.544 |
| Male/female | 70/226 | 72/213 | 0.939 |
| Pathological tumor size [mm; ±SD (range)] | 8.3 ± 5.0 | 8.8 ± 5.5 | 0.356 |
| Operative time [min; ±SD (range)] | 50.5 ± 10.4 | 60.4 ± 11.5 | 0.006 |
| Pathological T classification (<T3/T3) | 157/139 | 167/118 | 0.178 |
| Pathological N classification(p N0 / p N1a) | 134/162 | 96/189 | 0.004 |
| Tumor side/contralateral side (+/+) | / | 61 | / |
| Tumor side/contralateral side (+/−) | / | 124 | / |
| Tumor side/contralateral side (−/+) | / | 4 | / |
| Tumor side/contralateral side (−/−) | / | 96 | / |
| Unifocal/Multifocal | 242/54 | 245/40 | 0.169 |
| Transient hypocalcemia | 40/296 | 47/285 | 0.315 |
| Transient laryngeal nerve palsy | 13/296 | 25/285 | 0.033 |
| Definitive laryngeal nerve palsy | 2/296 | 2/285 | 1.000 |
| Post-operation hemorrhage | 6/296 | 5/285 | 1.000 |
| Removed lymph nodes [±SD (range)] | 8.5 ± 5.8 | 12.5 ± 6.5 | 0.002 |
| Metastasized lymph nodes [±SD (range)] | 2.6 ± 1.5 | 2.88 ± 1.7 | 0.857 |
| PG numbers of auto-transplantation | 226/592 | 377/855 | 0.025 |
| The ratio of IONM | 90/296 | 85/285 | 0.879 |
| PTH (pre-operation) | 4.28 ± 1.50 | 4.18 ± .1.62 | 0.945 |
| CA (pre-operation) | 2.34 + 0.16 | 2.32 ± 0.10 | 0.243 |
| PTH (Postoperative 1 Day) | 2.83 ± 1.37 | 2.55 ± 1.21 | 0.010 |
| CA (Postoperative 1 Day) | 2.26 ± 0.10 | 2.26 ± 0.09 | 0.556 |
| PTH (Postoperative 6 months) | 3.93 ± 1.93 | 3.95 ± 1.99 | 0.915 |
| CA (Postoperative 6 months) | 2.37 ± 0.93 | 2.36 ± 0.95 | 0.949 |
| Number of tumor recurrence | 0/296 | 1/285 | 0.491 |
Fig. 1After separating the outer side of the thyroid gland and pulling the lower pole of the thyroid lobe upward and inside, then we could quickly find the RLN and protect the PG.
Fig. 2This is the anatomical display after bilateral central lymph node dissection (BCND). We can protect the recurrent laryngeal nerve and parathyroid gland well
Fig. 3This is the anatomical display after ipsilateral central lymph node dissection (ICND)
Risk factors for unilateral PTC with contralateral central lymph node metastasis
| Characteristics | contralateral side LN(+) | contralateral side LN(−) | |
|---|---|---|---|
| No. of patients | 65 | 220 | / |
| age | 42.4 ± 10.5 | 43.4 ± 11.9 | 0.554 |
| Male/female | 16/49 | 50/170 | 0.751 |
| Pathological T classification (<T3/T3) | 43/22 | 126/94 | 0.200 |
| Pathological tumor size(<10/≥10 mm) | 25/40 | 147/73 | 0.000 |
| Unifocal/Multifocal | 52/13 | 180/40 | 0.741 |
| lesion located in the lower pole | 31/34 | 114/106 | 0.559 |
| Tumor side LN (+/−) | 61/4 | 124/96 | 0.000 |
Multi-variable analysis for unilateral PTC with contralateral central lymph node
| variable | B | Standard error | Wald | df | Significance | OR value | 95.0% C.I.for EXP(B) | |
|---|---|---|---|---|---|---|---|---|
| The lower limit | The upper limit | |||||||
| Male/female | 0.434 | 0.509 | 0.637 | 1 | 0.436 | 1.527 | 0.535 | 4.211 |
| Pathological T classification (<T3/T3) | 0.865 | 0.538 | 2.588 | 1 | 0.112 | 2.413 | 0.816 | 6.925 |
| lesion located in the lower pole | 0.502 | 0.566 | 0.692 | 1 | 0.521 | 1.622 | 0.513 | 4.252 |
| Unifocal/Multifocal | 0.425 | 0.478 | 0.611 | 1 | 0.476 | 1.498 | 0.520 | 4.328 |
| Pathological tumor size (<10/≥10 mm) | 1.411 | 0.476 | 7.302 | 1 | 0.002 | 3.337 | 1.502 | 9.877 |
| Tumor side LN (+/−) | 1.334 | 0.589 | 4.523 | 1 | 0.001 | 3.774 | 1.109 | 10.882 |